Description: CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
Home Page: www.cstonepharma.com
New Bund Times Square
Shanghai,
201203
China
Phone:
86 21 6033 5000
Officers
Name | Title |
---|---|
Dr. Ningjun Jiang M.D., Ph.D. | Sr. Advisor |
Dr. Jianxin Yang M.D., Ph.D. | CEO, Sr. VP & Chief Medical Officer |
Mr. Jun Cheng | VP of Fin. |
Dr. Ngai Chiu Tse M.D., Ph.D. | Sr. VP & Chief Scientific Officer |
Mr. Ning He | Head of Legal Affairs & Joint Company Sec. |
Mr. Michael J. Choi M.B.A. | Chief Commercial Officer & Chief Strategy Officer |
Dr. - Zhou M.D. | GM of Greater China & Head of Commercial |
Ms. Yin Kwan Ho | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 4.9621 |
Price-to-Sales TTM: | 12.9528 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 569 |